Glioblastoma Multiforme Treatment Market Size- By Drug Class, By Treatment, By End Use - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Global Glioblastoma Multiforme Treatment Market Overview:

According to SPER Market Research, the Global Glioblastoma Multiforme Treatment Market is estimated to reach USD 6.05 billion by 2032 with a CAGR of 9.04%.

Glioblastoma multiforme (GBM) is an astrocytic-differentiated malignant tumour classified by the WHO as grade IV. The description and development of theories about these tumours have been covered in a wide range of historical records since they are among the most frequently clinically diagnosed central nervous system (CNS) oncological entry.The market is anticipated to grow as a result of a number of factors, including increased R&D, favourable regulatory settings, and the rising occurrence of glioblastoma multiforme. A strong pipeline is likely to significantly influence the glioblastoma multiforme (GBM) therapeutic market during the projected timeframe. It is estimated that the occurrence of brain tumours will drive market expansion throughout the course of the anticipated timeframe.The market is predicted to be boosted in the coming years by the growing acceptance of novel medicines and combination therapies. The need for a personalised treatment strategy to handle glioblastoma multiforme is anticipated to rise as a result of tumour heterogeneity and variance in patient-to-patient treatment approaches. The approval of new therapies is anticipated to lengthen the life expectancy of glioblastoma multiforme patients.

Impact of COVID-19 on the Global Glioblastoma Multiforme Treatment Market

The market for glioblastoma treatments has suffered as a result of COVID-19. During the COVID-19 pandemic, many ICU resources, including ventilators, personal protective equipment, and medical personnel, were diverted to COVID-19 cases, leading to the cessation of surgical neuro-oncology treatments. During the pandemic, there was instability in the ability to provide essential cancer patients with effective medical care. Additionally, it appears that individuals with glioblastoma are more susceptible to the COVID-19 infection, which led to the cancellation of surgeries and therapies. The worldwide glioma treatment market consequently has a significant impact on the market.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Drug Class, By Treatment, By End Use

Regions covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Amgen, Inc., Amneal Pharmaceuticals, Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd., Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd

Global Glioblastoma Multiforme Treatment Market Segmentation:

By Drug Class: Based on the Drug Class, Global Glioblastoma Multiforme Treatment Market is segmented as; Bevacizumab, Carmustine Wafers, Lomustine, Temozolomide, Others.

By Treatment: Based on the Treatment, Global Glioblastoma Multiforme Treatment Market is segmented as; Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy, Tumor Treating Field (TTF) Therapy.

By End Use: Based on the End Use, Global Glioblastoma Multiforme Treatment Market is segmented as; Ambulatory Surgical Centres, Clinics, Hospitals.

By Region: North America accounted for the largest percentage in recent years. Government support for the expansion of the healthcare sector, together with increased awareness of unusual ailments, simple access to top-notch medical facilities, and kind reimbursement policies, are some of the key factors driving regional market growth. Asia Pacific is anticipated to grow at the fastest rate throughout the projection period due to a number of factors, including the introduction of temozolomide generics, an improved economy, an increase in the world's elderly population, and rising healthcare investment.